← Browse by Condition

Medical Condition

parkinson disease

Total Trials

48

Recruiting Now

48

Trial Phases

Phase 1, Phase 2, Phase 1, Phase 2

Parkinson's disease research has expanded from symptomatic management (dopaminergic drugs, DBS) toward neuroprotective and disease-modifying strategies targeting alpha-synuclein aggregation β€” the protein implicated in Lewy body pathology. Prodromal biomarker studies now aim to identify patients years before motor symptoms appear, when intervention may be most effective.

Trials test alpha-synuclein antibodies (prasinezumab, cinpanemab), GBA1 gene therapy, adaptive deep brain stimulation (aDBS), GLP-1 agonists (liraglutide, semaglutide), and nilotinib for neuroprotection. Skin biopsy and cerebrospinal fluid alpha-synuclein assays are emerging as enrollment biomarkers.

Disease-modifying trials often restrict enrollment to early-stage patients (Hoehn & Yahr 1β€“2.5) within a few years of diagnosis to capture sufficient disease duration for benefit detection.

Frequently Asked Questions — parkinson disease Clinical Trials

How many clinical trials are currently recruiting for parkinson disease?

ClinicalMetric currently tracks 48 actively recruiting clinical trials for parkinson disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 48. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for parkinson disease?

parkinson disease research spans Phase 1 (3 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a parkinson disease clinical trial?

Eligibility criteria for parkinson disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

3

Phase 2

3

Top Sponsors

Radboud University Medical Center 3 trials

Fondazione Policlinico Universitario Agostino Gemelli IRCCS 2 trials

Abant Izzet Baysal University 2 trials

Shanghai Zhongshan Hospital 1 trial

University of Exeter 1 trial

Recruiting Clinical Trials

Neural Control of Breathing in Parkinson's Disease

Radboud University Medical Cen...

Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

Radboud University Medical Cen...

Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease

Shanghai Zhongshan Hospital

Serotonin Release in Premotor and Motor PD

University of Exeter

Biomarkers of Synaptic Damage in Multiple Sclerosis

NCT06466525 Phase 1

A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.

Longevity Biotech Australia Pt...

Parkinson Progression Marker Initiative Online (PPMI Online)

Michael J. Fox Foundation for ...

NCT04643327 Phase 2

Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

The University of Queensland

Serum Biomarkers in Parkinson's Disease at Different Stages

Fondazione Policlinico Univers...

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

United States, Austr...

Abbott Medical Devices

Long-Term Behavioral and Cognitive Outcomes of Deep Brain Stimulation in Patients With Parkinson's Disease

Fondazione IRCCS Ca' Granda, O...

Safety and Efficacy of Adaptive Deep Brain Stimulation

Italy, Netherlands, ...

Short- and Long-term Behavioral, Cognitive and Motor Outcomes of Frameless Deep Brain Stimulation in Patients With Parkinson's Disease: a Prospective Observational Study

Fondazione Policlinico Univers...

The GBA Multimodal Study in Parkinson's Disease

United States, Canad...

Pacific Parkinson's Research C...

Telerehabilitation Dual-Task Training for Parkinson's: A Multidimensional Evaluation

Turkey (Türkiye)

Fenerbahce University

Use of CereGate Therapy for Freezing of Gait in PD

AV133 Longitudinal Imaging Study in Patients With Early and Prdromal Parkinson's Disease

Xuanwu Hospital, Beijing

Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling

University Health Network, Tor...

Gait and Balance Impairment in Rare and Very Rare Neurological Diseases

Istituto Auxologico Italiano

Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

VA Office of Research and Deve...

FMRI-neurofeedback in Parkinson's Disease

Germany, Netherlands

Maastricht University Medical ...

Social & QoL Behaviors in Parkinson's Disease

Gregory Wallace

Intestinal Immunity in Neurologic Disease

Yale University

Sonification Techniques for Gait Training

Istituti Clinici Scientifici M...

DBS and Respiration

University of Oxford

NCT05152394 Phase 1

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease

Antigua and Barbuda

The Foundation for Orthopaedic...

VIM+PTT MRgFUS for PD

Chinese PLA General Hospital

Minimal Clinically Important Difference of the Box and Block Test in Parkinson

Turkey (Türkiye)

Pilot Study: Parkinson's Conventional Physiotherapy vs Home-based Telerehabilitation

Azienda Sanitaria Locale CN1 C...

Cortical Correlates of Gait in Parkinson's Disease: Impact of Medication and Cueing

Oregon Health and Science Univ...

Study on Preliminary Safety and Efficacy of Adaptive DBS Aligned to Locomotor States to Improve Locomotor Functions in Parkinson's Patients

The Effect of Spinal Mobilization on Respiratory Parameters in Parkinson's Disease Patients

Turkey (Türkiye)

Abant Izzet Baysal University

The Effect of Compensation Strategies on Gait Impairment in Parkinson's Disease

Radboud University Medical Cen...

Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries

Umeå University

Temporal Relationship Between Motor Fluctuations and Nonmotor Fluctuations

Seoul National University Hosp...

Implementing a National Biobank of PD With WGS and Functional Assessment of Polygenic Inheritance by iPSC Technology

IRCCS San Raffaele

NCT03457493 Phase 1, Phase 2

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

University of Alabama at Birmi...

Patient-Specific 3D Action Observation Training in Parkinson's Disease

Turkey (Türkiye)

Abant Izzet Baysal University

Movement Error-processes and Sensorimotor Adaptation in Parkinsonian Patient

Assistance Publique Hopitaux D...

Effect of Visual Feedback From the SpiroGym Mobile Application

General University Hospital, P...

Dual Frequency Stimulation in Parkinson's Disease

University of California, Davi...

Steps Against the Burden of Parkinson's Disease - TelAviv/Bologna

University of Kiel

SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

Bial - Portela C S.A.

Effectiveness of TeleVR App in Cognitive Decline and MCI Patients

IRCCS Centro Neurolesi Bonino ...

Research on the Brain Mechanism of taVNS in Regulating PD Motor Symptoms

The First Affiliated Hospital ...

Effect of Sensory Electrical Stimulation on Resting Tremors in Patients with Parkinson's Disease

Cairo University

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

University of Michigan

NCT06679374 Phase 2

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Related Conditions

multiple sclerosis (5) rem sleep behavior disorder (3) alzheimer disease (3) mild cognitive impairment (3) neurodegenerative diseases (2) neurodegeneration (2) movement disorders (2) stroke (2) prodromal stage (1) parkinsonian disorders (1) basal ganglia diseases (1) central nervous system diseases (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology